Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/1891
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorFERRAROTTO, Renata-
dc.contributor.authorHOFF, Paulo M.-
dc.date.accessioned2013-09-23T16:37:34Z-
dc.date.available2013-09-23T16:37:34Z-
dc.date.issued2013-
dc.identifier.citationCLINICAL COLORECTAL CANCER, v.12, n.1, p.1-7, 2013-
dc.identifier.issn1533-0028-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1891-
dc.description.abstractAngiogenesis is essential to cancer development and progression, and its inhibition has been shown to benefit patients with several different malignancies. A considerable number of antiangiogenic compounds have been evaluated for the treatment of colorectal cancer; but only bevacizumab and aflibercept were able to demonstrate a survival benefit in phase III trials. In this review, we discuss important aspects of the interrelationship between tumor cells and the microenvironment leading to tumor progression, with a focus on angiogenesis. Clinical data on antiangiogenic therapies for colorectal cancer in the metastatic and adjuvant settings, as well as the potential use of antiangiogenics beyond tumor progression are analyzed. The need to identify surrogate biomarkers towards a more personalized approach in oncology is emphasized as this is becoming increasingly important in drug development. Clinical Colorectal Cancer, Vol. 12, No. 1, 1-7 (C) 2013 Elsevier Inc. All rights reserved.-
dc.description.sponsorshipSanofi-Aventis-
dc.description.sponsorshipRoche-
dc.language.isoeng-
dc.publisherCIG MEDIA GROUP, LP-
dc.relation.ispartofClinical Colorectal Cancer-
dc.rightsrestrictedAccess-
dc.subjectAflibercept-
dc.subjectBevacizumab-
dc.subjectCediranib-
dc.subjectMetastatic colorectal cancer-
dc.subjectVatalanib-
dc.subject.otherendothelial growth-factor-
dc.subject.otheradvanced gastrointestinal malignancies-
dc.subject.otheroxaliplatin-based chemotherapy-
dc.subject.otherphase-ii trial-
dc.subject.otherpredictive markers-
dc.subject.other1st-line treatment-
dc.subject.otherantitumor-activity-
dc.subject.otherplus bevacizumab-
dc.subject.otherptk787/zk 222584-
dc.subject.otherhuman tumor-
dc.titleAntiangiogehic Drugs for Colorectal Cancer: Exploring New Possibilities-
dc.typearticle-
dc.rights.holderCopyright CIG MEDIA GROUP, LP-
dc.identifier.doi10.1016/j.clcc.2012.06.002-
dc.identifier.pmid22763196-
dc.subject.wosOncology-
dc.type.categoryreview-
dc.type.versionpublishedVersion-
hcfmusp.author.externalFERRAROTTO, Renata:Hosp Sirio Libanes, Dept Oncol, BR-01308050 Sao Paulo, Brazil-
hcfmusp.description.beginpage1-
hcfmusp.description.endpage7-
hcfmusp.description.issue1-
hcfmusp.description.volume12-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000315833500001-
hcfmusp.origem.id2-s2.0-84874677879-
hcfmusp.publisher.cityDALLAS-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAllegra CJ, 2011, J CLIN ONCOL, V29, P11, DOI 10.1200/JCO.2010.30.0855-
hcfmusp.relation.referenceBono P, 2011, ACTA ONCOL, V50, P569, DOI 10.3109/0284186X.2010.543696-
hcfmusp.relation.referenceBramswig ICH, 2010, J CLIN ONCOL S, V28-
hcfmusp.relation.referenceBrave SR, 2010, ANGIOGENESIS, V13, P337, DOI 10.1007/s10456-010-9190-0-
hcfmusp.relation.referenceBrower V, 2009, J NATL CANCER I, V101, P780, DOI 10.1093/jnci/djp150-
hcfmusp.relation.referenceCohn AL, 2010, J CLIN ONCOL S, V28(-
hcfmusp.relation.referenceCunningham D, 2008, J CLIN ONCOL, V26-
hcfmusp.relation.referencede Gramont A, 2011, J CLIN ONCOL S, V29-
hcfmusp.relation.referenceEichholz A, 2010, ONCOTARGETS THER, V3, P69-
hcfmusp.relation.referenceEllis LM, 2008, J CLIN ONCOL, V26, P5313, DOI 10.1200/JCO.2008.17.4540-
hcfmusp.relation.referenceEllis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403-
hcfmusp.relation.referenceFan F, 2012, J ONCOL, V2012, DOI 10.1155/2012/281261-
hcfmusp.relation.referenceFielding A, 2011, J CLIN ONCOL S15, V29-
hcfmusp.relation.referenceFolkman J, 2003, CANCER BIOL THER, V2, pS127-
hcfmusp.relation.referenceFuchs CS, 2007, J CLIN ONCOL, V25, P4779, DOI 10.1200/JCO.2007.11.3357-
hcfmusp.relation.referenceGarcia-Carbonero R, J CLIN ONCOL S, V30-
hcfmusp.relation.referenceGarrett CR, 2011, BRIT J CANCER, V105, P44, DOI 10.1038/bjc.2011.182-
hcfmusp.relation.referenceGiantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305-
hcfmusp.relation.referenceGoede V, 2010, BRIT J CANCER, V103, P1407, DOI 10.1038/sj.bjc.6605925-
hcfmusp.relation.referenceGotink KJ, 2010, ANGIOGENESIS, V13, P1, DOI 10.1007/s10456-009-9160-6-
hcfmusp.relation.referenceGrimminger PP, 2012, PHARMACOGENOMICS J, V12, P404, DOI 10.1038/tpj.2011.29-
hcfmusp.relation.referenceGrothey A, 2010, J CLIN ONCOL S, V28-
hcfmusp.relation.referenceGrothey A, 2011, EUR J CANC, V47-
hcfmusp.relation.referenceGrothey A, 2012, J CLIN ONCOL S, V30-
hcfmusp.relation.referenceGrothey A, 2008, J CLIN ONCOL, V26, P5326, DOI 10.1200/JCO.2008.16.3212-
hcfmusp.relation.referenceGuiu B, 2010, GUT, V59, P341, DOI 10.1136/gut.2009.188946-
hcfmusp.relation.referenceHecht JR, 2011, J CLIN ONCOL, V29, P1997, DOI 10.1200/JCO.2010.29.4496-
hcfmusp.relation.referenceHecht JR, 2010, J CLIN ONCOL S15, V28-
hcfmusp.relation.referenceHirashima Y, 2011, INT J CANCER, V130, P2359-
hcfmusp.relation.referenceHoff PM, 2010, ANN ONCOL S8, V21-
hcfmusp.relation.referenceHurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691-
hcfmusp.relation.referenceJemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107-
hcfmusp.relation.referenceJurgensmeier JM, 2011, J CLIN ONCOL S, V29-
hcfmusp.relation.referenceKemeny NE, 2011, J CLIN ONCOL, V29, P884, DOI 10.1200/JCO.2010.32.5977-
hcfmusp.relation.referenceKIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0-
hcfmusp.relation.referenceKlement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829-
hcfmusp.relation.referenceKopetz S, 2009, J CLIN ONCOL, V27, P1732, DOI 10.1200/JCO.2009.21.2084-
hcfmusp.relation.referenceKopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252-
hcfmusp.relation.referenceKopetz S, 2011, J CLIN ONCOL S, V29-
hcfmusp.relation.referenceLee CG, 2000, CANCER RES, V60, P5565-
hcfmusp.relation.referenceLoupakis F, 2011, BRIT J CANCER, V104, P1262, DOI 10.1038/bjc.2011.85-
hcfmusp.relation.referenceMatsusaka S, 2011, CANCER-AM CANCER SOC, V117, P4026, DOI 10.1002/cncr.25977-
hcfmusp.relation.referenceMir O, 2011, ONCOLOGIST, V16, P1325, DOI 10.1634/theoncologist.2010-0002-
hcfmusp.relation.referenceMitry E, 2006, J CLIN INVEST, V25-
hcfmusp.relation.referenceMulder K, 2010, ONCOTARGET, V1, P515-
hcfmusp.relation.referenceNaumov GN, 2006, CELL CYCLE, V5, P1779-
hcfmusp.relation.referenceO'Connor JPB, 2009, CLIN CANCER RES, V15, P6674, DOI 10.1158/1078-0432.CCR-09-0731-
hcfmusp.relation.referenceO'Connor JPB, 2011, BRIT J CANCER, V105, P139, DOI 10.1038/bjc.2011.191-
hcfmusp.relation.referencePohl M, 2011, Z GASTROENTEROL, V49, P1398, DOI 10.1055/s-0031-1281752-
hcfmusp.relation.referenceRini BI, 2011, J NATL CANCER I, V103, P763, DOI 10.1093/jnci/djr128-
hcfmusp.relation.referenceRonzoni M, 2010, ANN ONCOL, V21, P2382, DOI 10.1093/annonc/mdq261-
hcfmusp.relation.referenceRyanne Wu R, 2009, J GASTROINTEST CANC, V40, P101-
hcfmusp.relation.referenceSaltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930-
hcfmusp.relation.referenceSaltz LB, 2007, J CLIN ONCOL, V25, P4793, DOI 10.1200/JCO.2007.12.8637-
hcfmusp.relation.referenceSamson B, 2011, J CLIN ONCOL, V29-
hcfmusp.relation.referenceSastre J, 2011, EUR J CANC, V47-
hcfmusp.relation.referenceSchmoll HJ, 2011, J CLIN ONCOL S, V29-
hcfmusp.relation.referenceSchmoll HJ, 2010, ANN ONCOL S8, V21-
hcfmusp.relation.referenceShapiro JD, 2011, J CLIN ONCOL S, V29-
hcfmusp.relation.referenceSimkens LHJ, 2010, ANN ONCOL, V21, P2447, DOI 10.1093/annonc/mdq640-
hcfmusp.relation.referenceSpratlin JL, 2010, J CLIN ONCOL, V28, P780, DOI 10.1200/JCO.2009.23.7537-
hcfmusp.relation.referenceSuenaga M, 2011, SURG TODAY, V41, P1067, DOI 10.1007/s00595-010-4432-8-
hcfmusp.relation.referenceSzmit S, 2011, KIDNEY BLOOD PRESS R, V35, P18-
hcfmusp.relation.referenceTabernero J, 2011, EUR J CANC, V47-
hcfmusp.relation.referenceTORRES IP, 1994, P NATL ACAD SCI USA, V91, P2081-
hcfmusp.relation.referenceVan Cutsem E, 2011, ANN ONCOL, V22, pv18-
hcfmusp.relation.referenceVan Cutsem E, 2011, J CLIN ONCOL, V29, P2004, DOI 10.1200/JCO.2010.29.5436-
hcfmusp.relation.referenceVerheul HMW, 2004, J PATHOL, V202, P5, DOI 10.1002/path.1473-
hcfmusp.relation.referenceVoest EE, 2011, J CLIN ONCOL S, V29-
hcfmusp.relation.referenceWatanabe M, 2009, HUM GENE THER, V20, P598, DOI 10.1089/hum.2008.169-
hcfmusp.relation.referenceWatanabe T, 2011, DIS COLON RECTUM, V54, P1026, DOI 10.1097/DCR.0b013e31821c44af-
hcfmusp.relation.referenceWei SC, 2005, GUT, V54, P666, DOI 10.1136/gut.2004.050831-
hcfmusp.relation.referenceWeickhardt AJ WD, 2011, J CLIN ONCOL S, V29-
hcfmusp.relation.referenceWelch S, 2010, ANN ONCOL, V21, P152-
hcfmusp.relation.referenceXu L, 2009, CANCER RES, V69, P7905, DOI 10.1158/0008-5472.CAN-09-2099-
hcfmusp.relation.referenceYchou M, 2011, J CLIN ONCOL S, V29-
dc.description.indexMEDLINE-
hcfmusp.remissive.sponsorshipRoche-
hcfmusp.remissive.sponsorshipSanofi-Aventis-
hcfmusp.citation.scopus11-
hcfmusp.scopus.lastupdate2022-05-06-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDR
Departamento de Radiologia - FM/MDR

Artigos e Materiais de Revistas Científicas - HC/InRad
Instituto de Radiologia - HC/InRad

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_HOFF_Antiangiogehic_Drugs_for_Colorectal_Cancer_Exploring_New_Possibilities_2013.PDF
  Restricted Access
publishedVersion (English)322.43 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.